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This mini-review highlights the latest advances in the chemistry and biology of Pluronic® triblock
copolymers. We focus on their applications in medicine, as drug delivery carriers, biological response
modiﬁers, and pharmaceutical ingredients. Examples of drug delivery systems and formulations currently
in clinical use, clinical trials or preclinical development are highlighted. We also discuss the role that
Pluronic® copolymers may play in the innovative design of new nanomedicines in the near future.Introduction
The design and fabrication of nanosized objects by using
nanotechnology tools have recently resulted in a number of
conceptual advances, and now directly impact other elds, such
as neuroscience, medicine, and energy.1–4 The last decades have
seen the emergence of new nanomaterials and the development
of safer and more eﬀective medicines (nanomedicines) opening
up new perspectives for addressing social and environmental
critical issues.5 Among those, synthetic polymer therapeutics
are of particular interest in medicine, owing to their synthetic
versatility as well as their tuneable and unique properties.6 A
number of biologically active polymer–drug conjugates and
polymeric formulations, such as micelles, hydrogels andna¨ıs Pitto-Barry was born in
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hemistry 2014polymer-coated nanoparticles, are currently in clinical devel-
opment.7 The most commonly used polymers for applications
in medicine include polyethylene glycol (PEG), poly(D,L-lactide-
co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(glutamic acid)
(PGA), poly(caprolactone) (PCL), N-(2-hydroxypropyl)-methacry-
late (HPMA) copolymers, and poly(amino acids).8,9 The wide
utilisation of amphiphilic block copolymers in nanomedicine
not only stems from their attractive fundamental properties
useful in solving drug delivery problems, but also from possible
intrinsic biological activity.
The class of ABA triblock copolymers commercially available
as Pluronic® (non-proprietary name “poloxamers”) oﬀers a pool
of more than 50 amphiphilic,10 water-soluble and polymorphic
materials (A¼ hydrophilic block poly(ethylene oxide) (PEO) and
B¼ hydrophobic block poly(propylene oxide) (PPO); Fig. 1). The
original manufacturer BASF introduced a specic nomenclature
for those copolymers consisting of a letter indicating theNicolas Barry received his MSc
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Fig. 1 Molecular structure of a Pluronic® triblock copolymer (left) and
the Pluronic® grid adapted from ref. 11 and 12 (right; colour code:
physical state of copolymers under ambient conditions: green¼ liquid;
red ¼ paste; orange ¼ ﬂake).
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View Article Onlinemorphism of each copolymer (liquid (L), paste (P), and ake (F))
followed by one or two gures referring to the Pluronic® grid
shown in Fig. 1,11,12 and providing 1/300 of the molar mass of
the PPO block per unimer. The last digit shows one-tenth of the
molar mass percentage of PEO content per unimer. As an
example, P123 and P103 are both pastes, having the samemolar
mass percentage of PEO per unimer (30%) with longer PO units
for P123.
The physical and chemical properties of Pluronic® copoly-
mers can be nely tuned by modifying the molar mass ratio
between the PEO and PPO blocks (from 1 : 9 to 8 : 2), which
directly modies the in vivo properties and interactions with
cells and cell membranes, and provides high potential for the
design of innovative nanomedicines and new biomaterials.
In this article we review the properties that make Pluronic®
block copolymers unique nanotechnology tools and highlight
some areas of the current interest in their biochemistry. We
focus especially on the relationship between the physical and
chemical properties of Pluronics® and their utilisation in
medicine as drug delivery systems, pharmaceutical ingredients
and biological response modiers. Formulations currently in
clinical use, clinical trials or preclinical development are high-
lighted and discussed based on the latest signicant advances.
Pluronics® as nanocarriers for drug delivery
In the early 1960s, the emergence of lipid vesicles13 had been a
conceptual advance that paved the way for the development of
nanomedicines. Such development led to the approval for
clinical use of a dozen of nanotechnology therapeutic products.
Among those, nanoparticles made of polymers (NPs) are of
particular interest owing to their synthetic versatility as well as
their tuneable properties. Their utilisation as drug delivery
systems originates from their ability to navigate the drug cargo
in vivo environment, combined with potential targeting and
control of the drug concentration and distribution at the tissue,
cell, and subcellular levels.8 They also provide control of drug
solubility, by either increasing the aqueous solubility of highly
lipophilic drugs or decreasing the solubility of molecules which
might otherwise be rapidly excreted, increase the circulation
time in blood compared to the corresponding free drug, and
may also allow multidrug delivery and theranostics.43292 | Polym. Chem., 2014, 5, 3291–3297As early as 1994, it was demonstrated that nanospheres,
synthesised from amphiphilic copolymers composed of two
biocompatible blocks (including a polyethylene glycol(PEG)-
block), exhibit dramatically increased blood circulation times
and low liver accumulation in mice.14 This discovery was fol-
lowed by numerous reports of PEGylated NPs with various
architectures,15 and eventually led to PEG being listed as
“Generally Recognised as Safe” (GRAS) by the FDA, and to the
clinical translation of a number of PEGylated NPs.8 A number of
PEG-containing block copolymers were then developed and
among them, the amphiphilic and polymeric characters of
Pluronic® block copolymers have raised growing interest for the
design of drug delivery systems. In water, and above the critical
micelle concentration, these triblock copolymers self-assemble
in core–shell micelles comprising hydrophobic PPO blocks as
core and hydrated PEO blocks as corona.16 Such polymeric
micelles (typically smaller than 100 nm) possess a core–shell
structure and poorly water-soluble drugs can be incorporated
into the PPO hydrophobic core and protected from inactivation
in biological media.
The interest in using poloxamer polymers as drug delivery
systems is not recent, and the rst anticancer micellar formu-
lation to reach clinical evaluation was actually a mixture of the
anticancer drug doxorubicin (Dox; Fig. 2) with Pluronics® L61
and F127 micelles (SP1049C, currently developed by Supratek
Pharma Inc.).17 The recent result of a phase II study of SP1049C
in patients with advanced adenocarcinoma of the oesophagus
and gastroesophageal junction shows a notable antitumor
activity and favourable safety prole for SP1049C in such
cancers.18 Currently, Supratek Pharma Inc. indicates that
SP1049C is in clinical phase 3-stage study for the treatment of
cancers that are resistant to doxorubicin. SP1049C has been
designated as an orphan drug for carcinoma of the oesophagus
and in gastric cancers in the U.S. and is ready to enter a pivotal
international clinical phase 3 study. In 2013, Kabanov, a co-
founder of Supratek Pharma, Inc., and co-workers reported the
ability of SP1049C to deplete cancer stem cells (highly tumori-
genic cells with high proliferation potential that are believed to
drive tumor growth and progression) and decrease tumorige-
nicity and aggressiveness of cancer cells in vivo, opening up a
potential broader spectrum of action for SP1049C (e.g. in
leukemia and breast cancer).19
The encapsulation of Dox in the Pluronic® micelles shis its
biodistribution, which leads to a better accumulation of the
micellar drug in the tumors compared to the free drug, a
superior antitumor activity over Dox in a wide range of doxo-
rubicin-sensitive and -resistant human solid and hematopoietic
malignancies, and also delays the emergence of Dox-resistance
mechanisms. Importantly, the Pluronic® copolymers not only
induce the modulation of Dox pharmacokinetic parameters, but
are also directly involved in the biological eﬀect of the formu-
lation. Indeed, the P-glycoprotein function in the cell
membrane of Dox-resistant cancer cells is disrupted by
Pluronic® L61 which also selectively depletes cellular ATP.20
Other clinically used anticancer drugs have been recently
encapsulated in Pluronic® copolymer micelles. Docetaxel (DTX;
Fig. 2), a semi-synthetic analog of paclitaxel exhibits potencyThis journal is © The Royal Society of Chemistry 2014
Fig. 2 Molecular structures of doxorubicin, paclitaxel, docetaxel and physicochemical characteristics of some of the discussed Pluronic® block
copolymers.
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View Article Onlineagainst a variety of solid tumors but is impaired by poor
aqueous solubility, rapid phagocytic activity, renal clearance,
and non-selective distribution. DTX is clinically used in a
formulation with the non-ionic surfactant Tween 80 (poly-
sorbate 80).21 This formulation, named Taxotere®, was
approved by the FDA in 2004. However, Taxotere® leads to
serious side eﬀects, such as hypersensitivity, nephrotoxicity,
neurotoxicity, and incompatibility with common polyvinyl
chloride intravenous administration sets.22 In 2013,23 Fang and
co-workers demonstrated that DTX encapsulated in Pluronic®
P105 and F127 mixed micelles displays a higher cytotoxicity
towards A549-Taxol resistant cancer cells than Taxotere®
injections. Moreover, 1.85 longer blood time circulation,
3.82 larger area under the plasma concentration–time curve
and in vivo therapeutic improvement were observed with DTX-
loaded P105/F127 mixed micelles compared to Taxotere®.
Nonetheless, further studies will be required for evaluating the
toxicity and potential side-eﬀects induced by this Pluronic®
formulation.
In 2002,24 Kabanov and co-workers comprehensively
reviewed the utilisation of Pluronic® block copolymers for gene
delivery. Their ability to increase expression of genes delivered
into cells using non-viral vectors, to increase the transfection
with adenovirus and lentivirus vectors, to conjugate with poly-
cations, to condense DNA and to form polyplexes, and the
regional increase of naked DNA expression in tumors raised
considerable attention for gene delivery applications. Since
then, a number of promising results have been reported,
including the novel poloxamer Synperonic® F108 which
enhances lentiviral transduction over the best-in-class poly-
brene-assisted transduction,25 and a series of small-sized poly-
ethylenimine-conjugated Pluronic® copolymers (PCMs) thatThis journal is © The Royal Society of Chemistry 2014enhances the delivery of an antisense phosphorodiamidate
morpholino oligomer (PMO) in vitro and in dystrophic mdx
mice.26Pluronics® as biological response modiers
As briey exemplied in the previous section, Pluronic® block
copolymer drug delivery systems not only are capable of
encapsulating drugs and modifying their pharmacokinetic
properties, but also are potent biological response modiers
able to sensitise multidrug resistant (MDR) cancer cells and to
enhance drug transport across cellular barriers.27 Pluronic®
copolymer eﬀects in MDR cells are believed to be due to several
important biological mechanisms, including microviscosity
modication of the cellular membrane,28 inhibition of the
mitochondrial chain and ATP level depletion in cancer and
barrier cells (one of the biological modes of action of doxoru-
bicin-containing Pluronic® micelles SP1049C),29 inhibition of
drug eﬄux transporters, such as P-glycoprotein and multidrug
resistance proteins,30 pro-apoptotic signalling enhancement
and anti-apoptotic defence decrease in the MDR cell,31 inhibi-
tion of the glutathione/glutathione S-transferase detoxication
system,32 and abolishment of drug retention in cytoplasmic
vesicles.33
The release of cytochrome C induction and the increase of
reactive oxygen species (ROS) levels in the cytoplasm due to
mitochondrial disruption in MDR cells by Pluronic® P85
copolymers have also been recently demonstrated by Kabanov
and co-workers.34 Diﬀerential metabolic responses to Pluronic®
in MDR and non-MDR cells and selective respiration inhibition
in MDR cell mitochondria were particularly shown.34 The
mitochondrial disruption in MDR cells results in ROS levelPolym. Chem., 2014, 5, 3291–3297 | 3293
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View Article Onlineincrease and release of cytochrome C (Fig. 3), which leads to the
enhancement of the drug-induced apoptosis and contributes to
potent chemosensitisation of MDR tumours by the Pluronic®
P85 block copolymer.
Oxidative stress caused by the generation of ROS is a
particularly eﬀective method of killing cancer cells.35 ROS are
produced in a wide range of physiological processes, in partic-
ular by mitochondria, and act as a ‘double-edged sword’ in cell
health. On one hand, they play benecial roles in cellular sig-
nalling; on the other hand, uncontrolled excessive production
of ROS, or a diminished ability of cells to scavenge ROS, gives
rise to oxidative stress and subsequent damage to various
cellular components, including proteins, lipids and DNA.
Cancer cells being oen under increased oxidative stress
compared to normal cells, an element of selectivity is achieved
by further increasing the level of oxidative stress.
Remarkably, the eﬀect of Pluronic® block copolymers on
cancer cells dramatically depends on their chemical composi-
tions and on the molar mass ratio between the PEO and PPO
blocks (a quantied description of the key physicochemical
properties of some Pluronics® is shown in Fig. 2). For instance,
Pluronic® L61 (with an intermediate length of the PPO block
and a relatively hydrophobic structure) was found to be the
most eﬃcient poloxamer inhibitor of the drug eﬄux systems in
MDR cells but does not impact the P-glycoprotein function or
cellular ATP levels,36 whilst Pluronics® with long PPO blocks
(e.g. F127, P123, L121) and high hydrophobicity strongly modify
the microviscosity of plasma membranes and potently inhibit
the P-glycoprotein function, but suﬀer from poor cellular
uptake. Such dramatic diﬀerences in the Pluronic® biological
mechanisms oﬀer a rich pool of possible unimers and a
combination of unimers that may be used for designing NPs
with nely tuned and optimised properties, as both drug
delivery systems and biological response modiers.Fig. 3 Eﬀect of Pluronic® P85 on (A) ROS production and (B) cyto-
chrome C release in MCF7 and multidrug resistant MCF7/ADR cells.
Adapted from ref. 34.
3294 | Polym. Chem., 2014, 5, 3291–3297Pluronics® as surfactants, and gelation and coating agents for
pharmaceutical formulation
Pluronic® block copolymers are polymorph materials that cover
a range of gelation states from liquid to paste and solid,
depending on the molar mass ratios between the PEO and PPO
blocks (see the Pluronic® grid in Fig. 1). This structural versa-
tility makes them particularly attractive emulsifying, solubilis-
ing, and dispersing ingredients for pharmaceutical
formulation.37 Pluronic® copolymers are listed as excipients in
the U.S. and British pharmacopoeias and are widely used in a
variety of clinical applications.38,39 Some poloxamer-based
devices are also clinically utilised in the U.S. and in Europe, for
instance the Pluronic® 407 gel (LeGoo® from Pluromed Inc.)
used as oﬀ-pump coronary bypass (rapid gel injection aer
arteriotomy of the abdominal aorta in order to occlude the
vessel – Poloxamer 407 – becomes solid within a few seconds).40
A number of clinical trials now involve Pluronic® polymer
containing formulations (Table 1).
The amphiphilicity and surfactant properties of Pluronic®
triblock copolymers make them particularly suitable for poly-
mer decoration of up-conversion nanoparticles (UCNPs).
UCNPs polymer coating is a technology that has shown promise
for increasing the water-solubility, and stability of UCNPs and
for functionalising their surface. A range of methods have been
investigated for achieving stable and eﬃcient decorations,
including ligand exchange,41 ligand oxidation,42 electrostatic
adsorption,43 and surface graing.44
In 2012,45 the Pluronic® F127 was used as an oil-to-water
phase transfer for coating UCNPs. Such oil-to-water phase
transfer coating was exemplied with NaYF4:Yb,Er(Tm) nano-
particles (see Fig. 4 for the principle of this method). The
Pluronic® decoration allowed the production of highly stable
up-conversion nanoparticles with strong luminescence proper-
ties, low general toxicity and high biocompatibility, which
opens new perspectives for the application of UCNPs as bio-
imaging agents.Functionalised Pluronics® and innovative nanocarriers
The studies summarised in this review all point out the
importance of the chemical composition of the Pluronic® block
copolymer for the physicochemical and biological properties of
the resulting Pluronic® formulation. Hydrophobicity and
polymorphism are for instance crucial parameters for their
biological mode of action. The majority of poloxamer formula-
tions undergoing clinical trials relies either on their physical
state properties (e.g. gels for surgery applications, incorporation
as surfactants) or on the molar mass and size of the self-
assembled micelles (typically between 10 and 100 nm). Indeed,
to date, both clinically validated therapeutic and imaging NPs
usually target cancer cells in a passive way,4 and poloxamer NPs
do not make exception. Such a passive drug targeting is ach-
ieved by taking advantage of the enhanced permeability and
retention (EPR) eﬀect in tumour tissues.46 Tumour vasculature
is highly disorganised as compared to the vasculature in normal
tissues, and the vascular endothelium in tumours proliferates
rapidly and discontinuously. Nevertheless, the delivery of theThis journal is © The Royal Society of Chemistry 2014
Table 1 Some examples of industries/sponsors with Pluronic®-containing formulations in development or clinical trials. More details can be
found on the Clinical Trials website: http://www.clinicaltrials.gov/
Industry/sponsor Pluronic® containing formulation Use Stage
Supratek Pharma Inc. SP1049C: Doxorubicin + Pluronics®
L61 and F127
Advanced esophageal
adenocarcinoma
Phase III
Mast Therapeutics, Inc. Puried Poloxamer 188 (based on
Pluronic® F68)
Vaso-occlusive crisis Phase III
British Columbia Cancer Agency Topical amitriptyline 2%, ketamine
1%, and lidocaine 5% in Pluronic®
lecitine organogel
Neuropathic pain secondary to
radiation therapy
Phase III completed
CoDa Therapeutics, Inc. Nexagon®: Pluronic® gel Persistent corneal epithelial defects Phase II
Sancilio and Company, Inc. SC401B (Pluronic® F87 as a
surfactant)
Severe hypertriglyceridemia Phase III
Valentis VLTS-934 (Pluronic®Poloxamer
188)
Peripheral vascular disease Phase II completed
Fig. 4 Schematic illustration of UNCP coating through oil-to-water
phase transfer. Reproduced from ref. 45 with permission from The
Royal Society of Chemistry.
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View Article Onlineactive pharmaceutical ingredient (API) into specic intracellular
sites in cancer cells requires active targeting. Actively targeted
NPs may be internalised through clathrin-dependent endocy-
tosis pathways, caveolin-assistance, cell-adhesion-molecule
directed or lipid-ra-associated mechanisms, leading to endo-
some formation, which ultimately leads to lysosomes.47
The structural versatility of poloxamers and the relatively
simple chemical structure of these ABA copolymers make them
particularly suitable for chemical transformation and func-
tionalisation. For instance, a series of cationic functionalised
Pluronic® copolymers was obtained by graing poly-
ethylenimine with nonionic amphiphilic surfactant polyether-
Pluronic®.48 They have been shown to be promising DNA and
small interfering RNA/microRNA delivery systems. Paclitaxel
(Taxol®; Fig. 2), one of the most used chemotherapy drugs in
the treatment of a range of cancers including ovarian, breast
and non-small cell lung cancers, has also recently been encap-
sulated into Pluronic® F68 micelles.49 These micelles, further
immobilised with a glycol chitosan/heparin composite, benet
from both passive targeting via the EPR eﬀect and active tar-
geting achieved by the specic interactions between the
brinogen-derived products in the tumor tissue and the
heparin on the glycol chitosan/heparin composite.50 In addition
to being an elegant example of NP double targeting of cancerThis journal is © The Royal Society of Chemistry 2014cells and to potentially providing an alternative to the FDA
approved breast anticancer paclitaxel-loaded PEG-PLA micelles
(Genexol-PM; PLA ¼ poly-lactide), it also illustrates the versa-
tility of the Pluronic® block copolymers and the rich pool of NPs
synthetically accessible from such copolymers.
The ability of Pluronic® block copolymers to provide steric
stabilisation to lyotropic liquid crystalline particles might
also be of particular interest for the design of innovative drug
delivery systems.51–53 Nanostructured cubic lyotropic liquid
crystalline colloidal particles (or Cubosomes®)54 possess an
internal ordered structure made of lipid bilayers and water
channels.55 They have been proven both eﬃcient drug vectors
(via controlled release through diﬀusion) and suitable for
intravenous administration (being dispersed and stabilised
as sub-micron sized nanostructured particles).56–58 Despite
this promise, the stabilisation of such Cubosomes® remains
challenging, and only a few stabilisers have been reported.59,60
Among these, Pluronic® F127 has been demonstrated to be
the best known liquid crystal stabiliser.61 Nonetheless, the
need to use a high concentration (up to 1 wt% of the total
sample mass) to properly disperse the Cubosomes® and the
possible disruption and destabilisation of the internal liquid
crystalline structure of the Cubosomes® (Fig. 5) are two
limitations for the utilisation of Pluronic® F127 as a
stabiliser.61
Recently,62 by using high throughput methodologies to
prepare and characterise the dispersions of monoolein and
phytantriol, the capability of a range of Pluronics® for stabil-
ising Cubosomes® was investigated. In this work, Boyd,
Drummond, and co-workers showed that the hydrophilic-lipo-
philic balance (HLB), molar mass and cloud point of Pluronic®
are crucial physicochemical properties for the stabilisation of
liquid crystalline cubic phase particles. It was demonstrated
that Pluronic® F108 both maintains colloidal stability, and
preserves the integrity of the internal liquid crystalline structure
of the Cubosomes®, making it an excellent candidate as a lyo-
tropic liquid crystalline particle stabiliser and opening up new
perspectives for the design of innovative drug and biomedical
imaging agent encapsulation systems. Furthermore, this study
particularly highlights the importance of the relationshipPolym. Chem., 2014, 5, 3291–3297 | 3295
Fig. 5 Disruption and destabilisation of the internal liquid crystalline
structure from Pn3m (double diamond) to Im3m (primitive) due to the
utilisation of Pluronic® F127 for the dispersion of bulk monoolein. The
unit cell structure of (i) Im3m (A and B) and (ii) Pn3m (C and D) cubic
phases. Reproduced from ref. 62 with permission from The Royal
Society of Chemistry.
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View Article Onlinebetween Pluronic® physical and chemical properties and uti-
lisation in medicine.Conclusions
It is clear that the utilisation of nanotechnology tools for the
design of polymer nanoparticles, although being still an emer-
gent concept, has already shown tangible promise in medicine.
Pluronic® block copolymers are particularly suitable for the
exploration of bio-inspired, bioengineered and biomimetic NPs.
In parallel with the design of new Pluronic®-based drug delivery
systems and Pluronic®-containing formulations, great eﬀort
has also been devoted to elucidating their role in the activity
enhancement of the encapsulated drug, their biological mode
of action and metabolism.
We have tried to focus here particularly on recent advances
in the utilisation of Pluronic® block copolymers as drug
delivery systems, biological response modiers, and pharma-
ceutical ingredients and illustrated them with formulations
currently undergoing clinical trials. These examples demon-
strate that there is a wide scope for designing innovative
Pluronic® formulations, either by functionalising the polox-
amer with vectors on its surface which can target specic cell
receptors, or by combining diﬀerent types of poloxamers to
nely tune the biological properties of the resulting mixed
micelles.
Such a chemical and biological versatility suggests future
fundamental advances in the design of Pluronic®-based nano-
medicines, for instance by encapsulating hydrophobic mole-
cules with unusual modes of actions. We have recently shown
the importance of metals in medicine,63 and how nanotech-
nology may help to shape the future of medicinal inorganic3296 | Polym. Chem., 2014, 5, 3291–3297chemistry,4 and we believe that Pluronic® block copolymers are
called to play a signicant role in this future.Acknowledgements
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